RAC.AX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 geg. 2024 @ 09:10):

Stats
Dzisiejszy wolumen	21 196.00
Średni wolumen	149 809
Kapitalizacja rynkowa	197.81M
EPS	$0 ( 2024-02-25 )
Następna data zysków	( $0 ) 2024-07-28
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-17.00
ATR14	$0.0150 (1.28%)

Race Oncology Ltd Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Race Oncology Ltd Korelacja - Waluta/Towar

-0.43
( neutral )

-0.13
( neutral )

0.00
( neutral )

-0.49
( neutral )

0.41
( neutral )

Race Oncology Ltd Finanse

Annual	2023
Przychody:	$3.13M
Zysk brutto:	$2.85M (91.03 %)
EPS:	$-0.0617

FY	2023
Przychody:	$3.13M
Zysk brutto:	$2.85M (91.03 %)
EPS:	$-0.0617

FY	2022
Przychody:	$707 807
Zysk brutto:	$426 611 (60.27 %)
EPS:	$-0.0731

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.0794

Financial Reports:

No articles found.

Race Oncology Ltd

Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.